Benzinga · Oct 15, 2026
MaxCyte 13D Filing Shows Liontrust Investment Partners Reports 5% Stake In Co. As Of Oct. 14
https://www.sec.gov/Archives/edgar/data/1287098/000154420426000009/xslSCHEDULE_13D_X02/primary_doc.xml
MX
NASDAQ · MXCT
MaxCyte, Inc.
Healthcare · Medical - Devices
$1.43
Up+$0.13 (+10.00%)
Updated Oct 21, 2026, 2:54 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 170.68M
- P/E ratio
- -3.73
- Dividend yield
- 0.00%
- 52-week range
- $0.64 – $1.81
- Volume
- 1.39M
- Avg. volume
- 961.6K
Price performance · MXCT
MXCT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
MXCT closed at $1.43 after 21 trading sessions, up 15.32% for the selected period.
- Last close
- $1.43
- Period change
- +15.32%
- Period low
- $0.96
- Period high
- $1.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $1.29 | $1.4567 | $1.29 | $1.43 | 1.39M |
| Oct 19, 2026 | $1.30 | $1.31 | $1.27 | $1.30 | 986.46K |
| Oct 16, 2026 | $1.32 | $1.32 | $1.28 | $1.30 | 1.01M |
| Oct 15, 2026 | $1.27 | $1.31 | $1.255 | $1.30 | 3.79M |
| Oct 14, 2026 | $1.225 | $1.33 | $1.195 | $1.25 | 12.67M |
| Oct 13, 2026 | $0.9813 | $1.01 | $0.9361 | $0.9643 | 327.91K |
| Oct 12, 2026 | $1.01 | $1.01 | $0.9722 | $0.995 | 150.12K |
| Oct 9, 2026 | $1.02 | $1.03 | $0.99 | $1.01 | 240.01K |
| Oct 8, 2026 | $1.04 | $1.04 | $0.9636 | $1.02 | 476.76K |
| Oct 7, 2026 | $1.07 | $1.08 | $1.04 | $1.04 | 311.95K |
| Oct 6, 2026 | $1.09 | $1.105 | $1.05 | $1.09 | 333.15K |
| Oct 5, 2026 | $1.08 | $1.10 | $1.0601 | $1.08 | 194.9K |
| Oct 2, 2026 | $1.11 | $1.11 | $1.07 | $1.07 | 228.11K |
| Oct 1, 2026 | $1.12 | $1.16 | $1.08 | $1.09 | 397.07K |
| Sep 30, 2026 | $1.19 | $1.20 | $1.12 | $1.12 | 346.51K |
| Sep 29, 2026 | $1.18 | $1.23 | $1.16 | $1.18 | 542.86K |
| Sep 28, 2026 | $1.16 | $1.17 | $1.14 | $1.16 | 284.73K |
| Sep 25, 2026 | $1.20 | $1.20 | $1.16 | $1.17 | 415.92K |
| Sep 24, 2026 | $1.19 | $1.21 | $1.17 | $1.19 | 231.94K |
| Sep 23, 2026 | $1.24 | $1.24 | $1.19 | $1.19 | 251.79K |
| Sep 22, 2026 | $1.22 | $1.25 | $1.20 | $1.24 | 259.67K |
Latest MXCT news
The latest Smart Investors Daily articles mentioning MXCT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MXCT research
Overview
Company profile and research snapshot.
Company profile
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | Buy | — |
| Aug 11, 2025 | BTIG | Neutral | — |
| Aug 7, 2025 | William Blair | Market Perform | — |
| Mar 12, 2025 | Stifel | Buy | — |
| Apr 23, 2024 | Stephens & Co. | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 14, 2026
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance. Preliminary Third Quarter Revenue Core
Benzinga · Oct 14, 2026
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
Yahoo · Oct 6, 2026
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
